T小组上尉筹集了2 000万欧元,以推进其TCR-T疗法CT127,成为先进固态肿瘤的第一阶段试验。 Captain T Cell raised €20M to advance its TCR-T therapy CTC127 into a Phase I trial for advanced solid tumors.

T小组上尉筹集了2 000万欧元的股本融资,以推进其领先的TCR-T疗法(CTC127),将固态肿瘤中的MAGE-A4作为目标,进入称为TOMATA的第一阶段临床试验。 Captain T Cell raised EUR 20 million in equity financing to advance its lead TCR-T therapy, CTC127, targeting MAGE-A4 in solid tumors, into a Phase I clinical trial called TOMATA. 这场审判由德国柏林Charité大学Antonia Busse教授(Charité-Universitaetsemedizin Berlin)的Antonia Busse教授主持,将涉及8个德国癌症中心和高级肺癌、膀胱癌、胃癌、卵巢癌、头癌和颈癌的住院病人。 The trial, led by Prof. Antonia Busse at Charité – Universitaetsmedizin Berlin, will involve eight German cancer centers and enroll patients with advanced lung, bladder, gastroesophageal, ovarian, and head and neck cancers. 这笔资金支持开发该公司的自动化和全方位的TCR-T平台,包括一个活体应用平台,并依靠一个专有工程工具箱,旨在提高T细胞的性能。 The funding supports development of the company’s autologous and allogeneic TCR-T platforms, including an in vivo application, and builds on a proprietary engineering toolbox designed to enhance T cell performance.